Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 16/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 16/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 16/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 16/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 16/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 16/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433157 | 0.86 | ALDH1A1 (0.41) | NR2E1USP30ALDH1A1LMNAMAPT | |
| SCHEMBL1616168 | 0.83 | ALDH1A1 (0.49) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6127819 | 0.83 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7935796 | 0.81 | TSHR (0.43) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1616782 | 0.81 | PSEN1 (0.45) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20085589 | 0.81 | MAPT (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29878133 | 0.81 | MAPT (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16923520 | 0.80 | NR2E1 (0.43) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1927286 | 0.80 | NR2E1 (0.52) | NR2E1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28980187 | 0.80 | ALDH1A1 (0.49) | NR2E1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481829-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-04-07 | — | — | EP | disclosed |
| US-10669276-B2 | Fused pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190256517-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2958919-B1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3481829-A1 | FUSED PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018007331-A1 | FUSED PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-11 | — | — | WO | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| CN-1437603-A | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | CN | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| CN-1322203-A | Heterocyclic aminomethyl oxazolidinones as antibacterial agents | ASTRA ZENECA N V (SE) | 2001-11-14 | — | — | CN | disclosed |
| CN-1311787-A | oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | ASTRA ZENECA CO LTD (SE) | 2001-09-05 | — | — | CN | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | NR2E1 1608/4885PSEN1 2690/4885PSEN2 2820/4885 |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | SMN1; SMN2, FUS, SYNCRIP | NR2E1 2871/4885PSEN1 187/4885PSEN2 42/4885 |
| US-20190256517-A1 | FUSED PYRIMIDINE DERIVATIVES | C9, APP, HPGDS | NR2E1 3715/4885PSEN1 16/4885PSEN2 32/4885 |
| US-10669276-B2 | Fused pyrimidine derivatives | APP, APOB, C9 | NR2E1 3361/4885PSEN1 11/4885PSEN2 18/4885 |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | NR2E1 373/4885PSEN1 3839/4885PSEN2 4263/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | NR2E1 819/4885PSEN1 4562/4885PSEN2 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.